AffiliationDepartment of Endocrinology, Christie Hospital, Manchester, England.
MetadataShow full item record
AbstractPegvisomant is a pegylated analog of growth that functions as a growth hormone receptor antagonist. The drug is capable of normalizing serum IGF-I concentrations (the chief mediator of disease activity in acromegaly) in 97% of patients, and therapy is associated with significant improvements in the symptoms and signs of GH excess. Biochemical control may be achieved with pegvisomant in patients wholly or partially resistant to somatostatin analogs, and there are emerging data to suggest that the drug may be particularly suitable for patients with acromegaly and co-existent diabetes mellitus.
CitationTreatment of pituitary tumors: pegvisomant. 2005, 28 (1):111-4 Endocrine
- Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.
- Authors: Paisley AN, Trainer P, Drake W
- Issue date: 2004 Mar
- Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.
- Authors: Tritos NA, Biller BM
- Issue date: 2017 Feb
- Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
- Authors: Rix M, Laurberg P, Hoejberg AS, Brock-Jacobsen B
- Issue date: 2005 Aug
- Clinical use of pegvisomant for the treatment of acromegaly.
- Authors: Drake WM, Trainer PJ
- Issue date: 2003
- Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
- Authors: Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ
- Issue date: 2000 Apr 20